IN8bio starts Phase 2 GBM trial (INB-400) and completes Phase 1 dose escalation (INB-100)

IN8BIO, INC.

Enrollment open for Phase 2 trial of INB-400 in newly diagnosed GBM; plans ~40 patients in Arm A; primary endpoint 12-month OS.
Dose escalation phase of Phase 1 INB-100 trial in leukemia closed; clinical update expected at ASH Dec 9-12, 2023.
As of April 2023, 100% of evaluable patients (n=7) on INB-100 in durable complete remission; one patient progression-free >3 years.
First activated sites for INB-400: University of Louisville and Cleveland Clinic; INB-400 received FDA Orphan Drug Designation April 2023.
R&D Day held October 12, 2023; webcast available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.